Hyperhomocysteinemia is a risk factor for cardiovascular disease and stroke. Like many other cardiovascular risk factors, hyperhomocysteinemia produces endothelial dysfunction due to impaired bioavailability of endothelium-derived nitric oxide (NO). The molecular mechanisms responsible for decreased NO bioavailability in hyperhomocysteinemia are incompletely understood, but emerging evidence suggests that asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO synthase, may be a key mediator. Homocysteine is produced during the synthesis of ADMA and can alter ADMA metabolism by inhibiting dimethylarginine dimethylaminohydrolase (DDAH). Several animal and clinical studies have demonstrated a strong association between plasma total homocysteine, plasma ADMA, and endothelial dysfunction. These observations suggest a model in which elevation of ADMA may be a unifying mechanism for endothelial dysfunction during hyperhomocysteinemia. The recent development of transgenic mice with altered ADMA metabolism should provide further mechanistic insights into the role of ADMA in hyperhomocysteinemia.
Introduction
Homocysteine is a sulfur-containing amino acid that functions as a key intermediate in methionine metabolism. It is produced as a byproduct of methyl transfer reactions, which are important for the methylation of nucleic acids, proteins (including proteins methylated on arginine residues), neurotransmitters and phospholipids. 1 Plasma total homocysteine (tHcy) is a mixture of homocysteine and its disulfide derivatives, which include homocystine, homocysteine-cysteine mixed disulfide, and protein-bound disulfides. 2 Plasma levels of tHcy are normally less than 12 mol/l. 3 Hyperhomocysteinemia is a pathological condition characterized by elevation of plasma tHcy. It can be caused by genetic defects in the metabolism of homocysteine or methionine, or nutritional deficiency of folate, pyridoxine (vitamin B 6 ), or cobalamin (vitamin B 12 ). Hyperhomocysteinemia may also occur in patients with renal dysfunction, alcoholism, or hypothyroidism, and in those taking certain medications (e.g. niacin, fibrates, methotrexate, isoniazid, L-dopa, theophylline, phenytoin, nitrous oxide, and trimethoprim). 3 The hypothesis that hyperhomocysteinemia is a risk factor for cardiovascular disease was proposed over 30 years ago by McCully, who observed advanced vascular lesions in children with severe hyperhomocysteinemia (plasma tHcy Ͼ200 mol/l) caused by inborn errors of methionine metabolism. 4 Since that time, a large number of epidemiological studies have demonstrated that moderate hyperhomocysteinemia (plasma tHcy between 12 and 50 mol/l) is associated with increased risk of stroke and cardiovascular disease. 5, 6 Plasma tHcy can be lowered by oral administration of folic acid or combinations of B vitamins, and several clinical trials are under way to test the potential benefits of homocysteine-lowering therapy for the secondary prevention of stroke and cardiovascular disease. 7 In this review we discuss the metabolism of homocysteine, the vascular endothelial effects of hyperhomocysteinemia observed in animal models, and the possible role of asymmetric dimethylarginine (ADMA) in the pathogenesis of homocysteine-induced vascular dysfunction.
Homocysteine metabolism
Homocysteine lies at a critical branch point in methionine metabolism (Figure 1 ). In the methionine cycle, methionine is converted to S-adenosylmethionine (SAM), which serves as a methyl donor for methyl transferases, including the protein arginine methyl transferases that methylate protein arginine residues. 1 A major product of SAM-dependent methyl transfer reactions is S-adenosylhomocysteine (SAH), which is reversibly hydrolyzed to homocysteine.
Once formed inside the cell, homocysteine can be either metabolized to cystathionine or undergo remethylation to form methionine ( Figure 1 ). Conversion of homocysteine to cystathionine is catalyzed by the vitamin B 6 -dependent enzyme cystathionine ␤-synthase (CBS). In most tissues, the major pathway for homocysteine remethylation is catalyzed by the vitamin B 12 -dependent enzyme methionine synthase (MS). This reaction utilizes 5-methyltetrahydrofolate, which is generated by 5,10-methylene tetrahydrofolate reductase (MTHFR). In the liver and kidney, some homocysteine is remethylated to methionine by the enzyme betaine:homocysteine methyltransferase. 1 Homocysteine also can be exported into the extracellular fluid and blood, where it may undergo oxidation or disulfide exchange reactions with plasma proteins. 8
Animal models of hyperhomocysteinemia
Several methods have been developed to produce hyperhomocysteinemia in experimental animals such as monkeys, rats, rabbits, minipigs, and mice. 9 Common approaches include the administration of methionine or homocysteine and the use of folatedeficient diets. The recent development of mice with targeted defects in the genes that encode CBS, 10 MTHFR 11 and MS 12 has greatly expanded the number of experimental models available to investigators interested in hyperhomocysteinemia.
Endothelial dysfunction
One of the most consistent findings observed in animal models of hyperhomocysteinemia is impairment of endothelium-dependent relaxation of blood vessels. This condition, known as endothelial dysfunction, is associated with many cardiovascular risk factors, such as hypertension, hypercholesterolemia and diabetes, as well as hyperhomocysteinemia. 13 Endothelial dysfunction is not merely a marker of cardiovascular disease; it also has prognostic implications in predicting adverse clinical outcomes. 14 Impairment of endothelium-dependent vasomotor responses has been observed in experimental models of hyperhomocysteinemia in monkeys, 15 rats [16] [17] [18] and mice. [19] [20] [21] [22] Abnormal endothelium-dependent vasorelaxation also occurs in humans with acute hyperhomocysteinemia induced by oral methionine loading. [23] [24] [25] [26] [27] [28] Using a model of diet-induced hyperhomocysteinemia in monkeys, our group was among the first to demonstrate that moderate hyperhomocysteinemia is associated with endothelial dysfunction in vivo. 15 More recently, we have characterized endotheliumdependent relaxation responses in three murine models with targeted defects in homocysteine metabolism: (1) CBS-deficient mice; 19, 21, 22 (2) MTHFR-deficient mice; 29 and (3) MS-deficient mice. 30 Our approach has been to compare vascular responses in wild-type mice with those in mice heterozygous for a deficiency of CBS, MTHFR or MS. In many cases we have also introduced dietary interventions (high methionine and/or low folate diets) to produce a wider range of plasma tHcy concentrations.
Vascular responses were examined in aortic rings from heterozygous CBS-deficient (Cbsϩ/Ϫ) and wild type (Cbsϩ/ϩ) mice that were fed one of three diets: a control diet, a low folate diet, or a high methionine diet. 19, 21 Plasma levels of tHcy were influenced by both Cbs genotype and diet. When fed the control diet, Cbsϩ/ϩ and Cbsϩ/Ϫ mice had plasma tHcy levels of ϳ4 mol/l and ϳ6 mol/l, respectively. The highest levels of tHcy (20-30 mol/l) were seen in Cbsϩ/Ϫ mice fed the high methionine or low folate diets. Maximal relaxation to the endothelium-dependent dilator, acetylcholine, was significantly impaired in Cbsϩ/Ϫ mice fed the low folate or high methionine diets. 19, 21 Relaxation to the endothelium-independent vasodilator, nitroprusside, was not affected by Cbs genotype or diet. These findings showed that a genetic Methionine is activated to S-adenosylmethionine (SAM), which is a universal donor for methyl transfer reactions. S-adenosylhomocysteine (SAH) is a product of methyl transfer reactions that utilize SAM as a methyl donor. L-homocysteine is formed from the reversible hydrolysis of SAH. Levels of homocysteine are regulated by remethylation of homocysteine to methionine by the enzyme methionine synthase (MS) and trans-sulfuration of homocysteine to cystathionine by the enzyme cystathionine ␤-synthase (CBS). Homocysteine remethylation requires vitamin B 12 and 5,10-methyltetrahydrofolate (5-methyl THF), which is generated by 5,10-methylene tetrahydrofolate reductase (MTHFR). Homocysteine trans-sulfuration requires vitamin B 6 . In liver and kidney, some homocysteine is remethylated to methionine by betaine:homocysteine methyltransferase (BHMT), which uses betaine as a methyl donor and generates dimethylglycine (DMG) as a product. deficiency of CBS predisposes to endothelial dysfunction, especially under dietary conditions that stress the homocysteine metabolic pathway.
We have also found that endothelial function is impaired in cerebral arterioles (pial vessels of ϳ30 m baseline diameter) of CBS-deficient mice fed a high methionine diet. 22 The concentration of plasma tHcy associated with endothelial dysfunction in cerebral arterioles (10-15 mol/l) was lower than that necessary to produce endothelial dysfunction in the aorta (20-30 mol/l). Similar findings have been obtained in MTHFR-deficient and MS-deficient mice. 29, 30 It is apparent from these studies that cerebral microvessels are more sensitive to the vascular effects of mild hyperhomocysteinemia than large vessels such as the aorta. Small mesenteric arterioles in mice also appear to be highly sensitive to modest elevations of plasma tHcy. 20, 31, 32 
Mechanisms of endothelial dysfunction
The major functional abnormality underlying hyperhomocysteinemia-induced endothelial dysfunction appears to be related to decreased bioavailability of endothelium-derived nitric oxide (NO). 33 NO is a potent vasodilator that is produced by endothelial nitric oxide synthase (eNOS) in response to physiological stimuli such as acetylcholine, thrombin, bradykinin or shear stress, and is a major mediator of endothelium-dependent relaxation in both large arteries and small resistance vessels. 13 The mechanisms by which hyperhomocysteinemia decreases the bioavailability of endothelium-derived NO are not completely understood and may be multifactorial. 9, 33 Vasodilator responses to nitroprusside or nitroglycerin are normal, which suggests that the responsiveness of vascular smooth muscle to NO is relatively unaffected. 20 One mechanism for endothelial dysfunction during hyperhomocysteinemia may be oxidative inactivation of NO. Evidence for oxidative stress during hyperhomocysteinemia has been obtained in animals by using both pharmacological 20, 25, 27, 31, 34 and genetic 35, 36 approaches.
Several types of reactive oxygen species, including superoxide, hydrogen peroxide and hydroxyl radical, may contribute to the oxidative inactivation of endothelium-derived NO in hyperhomocysteinemia. 20, 33 Weiss et al found that treatment with the antioxidant L-2-oxothiazolidine-4-carboxylic acid improved endothelium-dependent vasodilator responses in mesenteric arterioles of CBS-deficient mice. 31 Using a similar approach, Bagi et al found that administration of the antioxidant vitamin C prevents endothelial dysfunction in gracilis muscle arterioles of hyperhomocysteinemic rats. 37 We found recently that dilatation of cerebral arterioles to acetylcholine in Cbsϩ/ϩ or Cbsϩ/Ϫ mice fed a high methionine diet is restored toward normal by the superoxide scavenger, tiron, 22 which suggests that superoxide is a key mediator of endothelial dysfunction in hyperhomocysteinemic mice. Generation of superoxide during hyperhomocysteinemia may result from activation of vascular NAD(P)H oxidases 22, 34 or uncoupling of eNOS, a condition in which eNOS produces superoxide rather than NO. 38 The hypothesis that homocysteine causes uncoupling of eNOS is supported by the observation that pharmacological inhibitors of eNOS block homocysteine-induced production of superoxide in cultured endothelial cells 39 and hyperhomocysteinemic mice. 22 Another possible mechanism of endothelial dysfunction in hyperhomocysteinemia is activation of the endoplasmic reticulum (ER) stress pathway. Homocysteine contains a reactive thiol group that can undergo disulfide exchange reactions 8 and disrupt the folding and processing of newly synthesized proteins in the ER. 40, 41 The cellular consequences of this condition, known as ER stress, include dysregulation of lipid metabolism, activation of inflammatory pathways, increased proteolysis of misfolded proteins, and apoptotic cell death. 42 Homocysteine has been shown to induce apoptotic cell death in cultured endothelial cells through activation of ER stress. 43 These observations suggest that hyperhomocysteinemia may lead to loss of functional endothelium by triggering ER stress.
ADMA: a potential unifying mechanism
Evidence is now emerging that elevation of the ADMA level may be a key mediator of decreased NO bioavailability during hyperhomocysteinemia. ADMA is an analogue of L-arginine that acts as a competitive inhibitor of eNOS. 44 In addition to inhibiting the production of NO, ADMA may also promote the uncoupling of eNOS, leading to increased production of superoxide and other reactive oxygen species, which, in turn, may cause a further decrease in bioavailability of NO. 38 A potential interaction between homocysteine and ADMA is suggested by the metabolic relationship between ADMA and methyl transfer reactions ( Figure 2 ). ADMA is produced from proteins that are methylated on arginine residues by type 1 protein arginine N-methyltransferases (PRMTs). 45, 46 PRMTs utilize SAM as a methyl donor and generate SAH (and ultimately homocysteine) as a byproduct. Since ADMA is formed from the proteolysis of methylated proteins (Figure 2) , 44, 47 we hypothesized that increased SAM-dependent protein methylation may result in both increased production of ADMA and increased generation of homocysteine. 48 In support of this hypothesis, we observed elevated plasma levels of ADMA in monkeys that were fed a hyperhomocysteinemic diet enriched in methionine and deficient in folate. 48 The hyperhomocysteinemic diet produced approximately three-fold increases in both plasma tHcy and plasma ADMA. Levels of ADMA correlated strongly with tHcy and with impairment of endothelium-dependent relaxation of the carotid artery in these monkeys. 48 We also found that plasma levels of ADMA increase rapidly after acute methionine loading in humans. 49 Eight hours after a standard oral methionine load (100 mg/kg), plasma ADMA increased from 1.4 Ϯ 0.2 to 2.0 Ϯ 0.2 M (p Ͻ 0.05), plasma tHcy increased from 6.9 Ϯ 1.6 to 28.4 Ϯ 3.5 M (p Ͻ 0.05), and flow-dependent vasodilatation of the brachial artery deceased by 80%. Brachial artery vasodilatation correlated inversely with plasma ADMA (p Ͻ 0.05) and directly with the L-arginine/ADMA ratio (p Ͻ 0.01). 49 Similar findings have been reported by Stühlinger et al. 50 Evidence for a metabolic link between homocysteine and ADMA has also been obtained from studies with cultured cells. Incubation of human endothelial cells with L-methionine or L-homocysteine produces dose-dependent increases in ADMA in the culture medium. 48, 51, 52 Similar effects of homocysteine have been observed with cultured neuronal cells. 53 Several case-control studies have demonstrated an association between hyperhomocysteinemia and elevation of plasma ADMA in humans with coronary artery disease, 54 peripheral arterial disease, 55 stroke, 56 or Alzheimers disease, 53 although at least one study found no association. 57 Collectively, these findings provide strong evidence that plasma ADMA is often elevated in hyperhomocysteinemia and support the hypothesis that ADMA may contribute to the impairment of NO bioavailability in this condition.
It is not known precisely how ADMA becomes elevated in hyperhomocysteinemia. We initially hypothesized that conditions that produce elevation of homocysteine, such as high methionine diets, may increase intracellular levels of SAM and thereby raise production of ADMA by promoting SAM-dependent PRMT activity. 48 This mechanism now seems unlikely, however, because hyperhomocysteinemia typically produces elevated tissue levels of SAH but not SAM. 21, 29 Although hyperhomocysteinemia probably does not enhance PRMT activity by increasing cellular levels of SAM, it remains possible that upregulation of PRMT expression may occur in hyperhomocysteinemia. This will be an important question to address in future research studies.
Other possible mechanisms of elevation of ADMA in hyperhomocysteinemia include its reduced renal excretion 57 and decreased activity of dimethylarginine dimethylaminohydrolase (DDAH), which metabolizes ADMA to citrulline. 58 Homocysteine has been shown to inhibit the activity of DDAH in vitro, 52 possibly through an oxidative reaction with its active site cysteine residue. 52 It is not yet known if this interesting reaction between homocysteine and DDAH occurs in vivo. To begin to address this question in a murine model, we measured the expression and activity of DDAH in the liver of hyperhomocysteinemic CBS-deficient mice. We found that mice with hyperhomocysteinemia had decreased levels of mRNA for the two major DDAH enzymes, DDAH-1 and DDAH-2 (S Dayal and SR Lentz, unpublished observations). These preliminary findings suggest that homocysteine may regulate DDAH expression as well as DDAH activity. It will be important in future studies to examine the effect of hyperhomocysteinemia on DDAH expression and activity in vascular tissue.
In summary, recent studies in cultured cells, animals and humans all indicate that ADMA is metabolically linked to homocysteine. These observations suggest a model in which elevation of ADMA may be a unifying mechanism for vascular dysfunction during hyperhomocysteinemia ( Figure 3 ). Homocysteine may elevate ADMA by inhibiting DDAH activity through a direct chemical reaction with its active site cysteine 52 or by inducing oxidative stress and subsequent oxidative inactivation of DDAH. 51 Alternatively, homocysteine may elevate ADMA by inducing ER stress and apoptosis, leading to increased proteolysis of proteins that contain methylarginine residues. Accumulation of ADMA in endothelial cells may inhibit eNOS, leading to decreased production of NO and endothelial dysfunction. Uncoupling of eNOS caused by ADMA or other oxidants such as peroxynitrite 59 may Homocysteine derived from the hydrolysis of SAH can be remethylated to methionine (Met), completing the methionine cycle. ADMA is derived from the proteolysis of proteins that contain methylated arginine residues and can cause endothelial dysfunction by inhibiting eNOS. The major pathway for metabolism of ADMA is via the enzyme dimethylarginine dimethylaminohydrolase (DDAH), which produces citrulline and methylamine. A small amount of ADMA is metabolized to alpha keto acids or excreted by the kidney.
accelerate production of superoxide and further decrease bioavailability of NO.
Perspectives
Over the past decade, numerous studies in animals and humans have demonstrated that hyperhomocysteinemia produces endothelial dysfunction due to decreased bioavailability of NO. Likely causes of decreased NO bioavailability in hyperhomocysteinemia include activation of cellular stress pathways and inhibition of eNOS by ADMA. The hypothesis that ADMA is a central mediator of vascular dysfunction in hyperhomocysteinemia (Figure 3) is supported by the close metabolic link between homocysteine and ADMA and the association between plasma tHcy, plasma ADMA, and endothelial dysfunction seen in many animal and clinical studies.
Several questions remain to be answered about the pathophysiological role of ADMA in hyperhomocysteinemia. Although most clinical studies have demonstrated that plasma ADMA is elevated in hyperhomocysteinemic persons, some have shown that hyperhomocysteinemia is not always associated with a significant elevation of plasma ADMA. 57, 60 Similar discrepancies have been seen in animal models of hyperhomocysteinemia. We observed a three-fold elevation of plasma ADMA in hyperhomocysteinemic monkeys 48 but only a small increase in plasma ADMA in CBS-deficient mice with hyperhomocysteinemia. 22 It is also not known if homocysteine-lowering therapy will result in lower plasma levels of ADMA and improved endothelial function, particularly in the presence of other cardiovascular risk factors. In the setting of pre-existing atherosclerosis, for example, therapy with B vitamins appears to be very effective at lowering plasma tHcy but may not decrease plasma ADMA or improve endothelial function. 48, 55 The ongoing multicenter trials of homocysteine-lowering therapy 61 may provide some answers to this question.
Another issue for future research studies will be to establish in vivo whether elevation of plasma ADMA during hyperhomocysteinemia is caused by its increased production, decreased metabolism, or another mechanism such as altered renal clearance. It will be particularly important to define the effects of hyperhomocysteinemia on the expression and activity of DDAH and PRMT in vascular tissues. Another major goal will be directly to test the hypothesis that elevation of ADMA causes endothelial dysfunction in hyperhomocysteinemia. The recent development of transgenic mice that overexpress DDAH 62 should facilitate such studies.
Figure 3
Model depicting the likely mechanisms of homocysteine-induced endothelial dysfunction and the possible role of ADMA. Homocysteine may inhibit DDAH activity directly or indirectly by inducing oxidative stress, leading to elevation of ADMA. Alternatively, homocysteine may elevate ADMA by inducing ER stress, leading to increased proteolysis of proteins containing methylarginine residues. Accumulation of ADMA in endothelial cells may inhibit nitric oxide synthase (NOS), leading to decreased production of nitric oxide and endothelial dysfunction. Uncoupling of NOS caused by ADMA or other oxidants may accelerate production of superoxide and further decrease bioavailability of nitric oxide.
